Your 'Pharmacy Show' questions answered by the MHRA GDP Inspectorate

Welcome to this, the next Inspectorate post.  My name is Madeleine Ault and I have been with MHRA for over 6 years now.  In that time I have inspected a wide range of wholesalers. These inspections cover large and small wholesalers, …

Supply of unlicensed medicines when an equivalent licensed product becomes available

blister pack

We've had a number of instances where licensed versions of commonly supplied unlicensed medicines have become available.  We want to remind stakeholders what to do if this happens. Recent examples of newly licensed products of this nature include fomicyt, 40mg/ml fosfomycin …

Good Manufacturing Practice (GMP) data integrity: a new look at an old topic, part 3

Vials in a laboratory

Data integrity is fundamental in a pharmaceutical quality system which ensures that medicines are of the required quality. A robust data governance approach will ensure that data is complete, consistent and accurate, irrespective of the format in which data is …

MHRA support for innovation - Inspectorate input to case studies

MHRA has now published 7 case studies highlighting the work of our Innovation Office and showing how we help organisations that are developing innovative medicines, medical devices or using novel manufacturing processes to effectively navigate regulatory processes, so they can progress their products …

The British Pharmacopoeia's new website - setting the standards

The launch of the new integrated British Pharmacopoeia website this week presents a great opportunity to explore this other group within the Inspection, Enforcement & Standards Division of MHRA. The British Pharmacopoeia (BP) makes an important contribution to the role of MHRA …

GPvP inspections of contract service providers

The Medicines and Healthcare products Regulatory Agency (MHRA) has embarked on a recent initiative to evaluate the feasibility of conducting stand-alone inspections of pharmacovigilance contract service providers. In July 2003 MHRA introduced a statutory pharmacovigilance inspection programme of marketing authorisation …